DCAL Stock Overview
Provides contract research and manufacturing services for the pharmaceutical, healthcare, and bio-technology industries worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Dishman Carbogen Amcis Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹220.01 |
| 52 Week High | ₹283.00 |
| 52 Week Low | ₹133.00 |
| Beta | 1.24 |
| 11 Month Change | 17.67% |
| 3 Month Change | 14.46% |
| 1 Year Change | 26.73% |
| 33 Year Change | -3.82% |
| 5 Year Change | 61.95% |
| Change since IPO | -37.51% |
Recent News & Updates
Recent updates
The Market Doesn't Like What It Sees From Dishman Carbogen Amcis Limited's (NSE:DCAL) Revenues Yet
Oct 15
Why Investors Shouldn't Be Surprised By Dishman Carbogen Amcis Limited's (NSE:DCAL) 31% Share Price Plunge
Jun 01Dishman Carbogen Amcis Limited's (NSE:DCAL) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Feb 25Dishman Carbogen Amcis (NSE:DCAL) Takes On Some Risk With Its Use Of Debt
Dec 29Is Dishman Carbogen Amcis (NSE:DCAL) Using Too Much Debt?
Jun 22Is Dishman Carbogen Amcis (NSE:DCAL) A Risky Investment?
Feb 14Dishman Carbogen Amcis (NSE:DCAL) Use Of Debt Could Be Considered Risky
Jun 22Shareholders Will Be Pleased With The Quality of Dishman Carbogen Amcis' (NSE:DCAL) Earnings
May 18Dishman Carbogen Amcis (NSE:DCAL) Has A Pretty Healthy Balance Sheet
Mar 14We Think Dishman Carbogen Amcis (NSE:DCAL) Is Taking Some Risk With Its Debt
Aug 23Why Dishman Carbogen Amcis Limited (NSE:DCAL) Could Be Worth Watching
Apr 29Dishman Carbogen Amcis (NSE:DCAL) Has A Somewhat Strained Balance Sheet
Mar 16A Look At Dishman Carbogen Amcis' (NSE:DCAL) Share Price Returns
Feb 23How Much Are Dishman Carbogen Amcis Limited (NSE:DCAL) Insiders Spending On Buying Shares?
Feb 05Is Dishman Carbogen Amcis Limited (NSE:DCAL) Popular Amongst Institutions?
Jan 23
What We Learned About Dishman Carbogen Amcis' (NSE:DCAL) CEO Compensation
Jan 10Is Now An Opportune Moment To Examine Dishman Carbogen Amcis Limited (NSE:DCAL)?
Dec 23Dishman Carbogen Amcis (NSE:DCAL) Takes On Some Risk With Its Use Of Debt
Dec 05Dishman Carbogen Amcis Limited (NSE:DCAL) Shares Could Be 27% Below Their Intrinsic Value Estimate
Nov 17If You Had Bought Dishman Carbogen Amcis' (NSE:DCAL) Shares Three Years Ago You Would Be Down 47%
Oct 23What We Learned About Dishman Carbogen Amcis' (NSE:DCAL) CEO Compensation
Sep 27Is Now The Time To Look At Buying Dishman Carbogen Amcis Limited (NSE:DCAL)?
Sep 06Dishman Carbogen Amcis Limited's (NSE:DCAL) Share Price Could Signal Some Risk
Aug 03Dishman Carbogen Amcis Limited's (NSE:DCAL) Price In Tune With Earnings
Jul 20Market Cool On Dishman Carbogen Amcis Limited's (NSE:DCAL) Earnings
Jul 06Shareholder Returns
| DCAL | IN Life Sciences | IN Market | |
|---|---|---|---|
| 7D | 23.0% | 1.2% | 0.3% |
| 1Y | 26.7% | 48.2% | 27.3% |
Return vs Industry: DCAL underperformed the Indian Life Sciences industry which returned 47.9% over the past year.
Return vs Market: DCAL matched the Indian Market which returned 27.2% over the past year.
Price Volatility
| DCAL volatility | |
|---|---|
| DCAL Average Weekly Movement | 9.0% |
| Life Sciences Industry Average Movement | 6.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: DCAL's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: DCAL's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 1,132 | Arpit Vyas | imdcal.com |
Dishman Carbogen Amcis Limited provides contract research and manufacturing services for the pharmaceutical, healthcare, and bio-technology industries worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It also manufactures and supplies bulk drugs, active pharmaceutical ingredients (APIs), and general and highly potent APIs; specialty chemicals comprising intermediates, fine chemicals, phosphoranes, solid quaternary ammonium compounds, wittig reagents, and various pharmaceutical and cosmetic-related products; vitamin D products and its analogues; hand and body wash, sanitizers, and antiseptics; and phase transfer catalysts, soft gel capsules, disinfectant formulations, cholesterol, lanolin-related products, and liquid and lyophilized sterile injectables.
Dishman Carbogen Amcis Limited Fundamentals Summary
| DCAL fundamental statistics | |
|---|---|
| Market cap | ₹34.49b |
| Earnings (TTM) | -₹1.74b |
| Revenue (TTM) | ₹26.19b |
1.3x
P/S Ratio-19.8x
P/E RatioIs DCAL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DCAL income statement (TTM) | |
|---|---|
| Revenue | ₹26.19b |
| Cost of Revenue | ₹7.25b |
| Gross Profit | ₹18.93b |
| Other Expenses | ₹20.68b |
| Earnings | -₹1.74b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.10 |
| Gross Margin | 72.31% |
| Net Profit Margin | -6.65% |
| Debt/Equity Ratio | 37.7% |
How did DCAL perform over the long term?
See historical performance and comparison